[1] Moucari R,Asselah T,Cazals-Hatem D,et al. Insulin resistance in chronic hepatitis C:association with genotypes 1 and 4,serum CHC RNA level,and liver fibrosis. Gastroenterology,2008,134(2): 416-423. [2] Naing C,Mak JW,Ahmed SI,et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol,2012,18(14):1642-1651. [3] Guo X,Jin M,Liu K, et al. Type 2 diabetes mellitus and the risk of hepatitis C virus infection:A systematic review. Sci Rep, 2013,3:2981. [4] Zein NN,Abdulkarim AS,Wiesner RH,et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C,alcohol,or cholestatic disease. J Hepatol,2000,32(2):209-217. [5] Mason AL,Lau JYN,Hoang N,et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology,1999,29(2):328-333. [6] Papatheodoridis GV,Chrysanthos N,Savvas S,et al. Diabetes mellitus in chronic hepatitis B and C:prevalence and potential association with the extent of liver fibrosis. J Viral Hepat,2006,13(5):303-310. [7] Chehadeh W,Abdella N,Ben-Nakhi A,et al. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol,2009,24(1): 42-48. [8] Antonelli A,Ferri N,Fallahi P,et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care,2005,28(10):2548-2550. [9] Chen HF,Li CY,Chen P,et al. Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc,2006,69(4):146-152. [10] Howard AA,Klein RS,Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis,2003,36(10):1318-1323. [11] Huang JF,Dai CY,Hwang SJ,et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area:an epidemiological link with virological implication. Am J Gastroenterol,2007,102(6):1237-1243. [12] Jadoon NA,Shahzad MA,Yaqoob R,et al. Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association. Virol J,2010,7:304. [13] Rouabhia S,Malek R,Bounecer H,et al. Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol,2010,16(27):3427-3431. [14] Lecube A,Hernandez C,Genesca J,et al. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care,2004,27(11): 2669-2675. [15] Romero-Gómez M,Vilria MDM,Andrade RJ,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 2005, 128(3):636-641. [16] Poustchi H,Negro F,Hui J,et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol,2008,48(1):28-34. [17] Chu CJ,Lee SD,Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther,2009,29(1):46-54. [18] Dai CY,Huang JF,Hsieh MY,et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol,2009,50(4):712-718. [19] Fattovich G,Covolo L,Pasino M,et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int,2011,31(1):66-74. [20] Bortoletto G,Scribano L,Realdon S,et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat,2010,17(7):475-480. [21] Akuta N,Suzuki F,Hirakawa M,et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of CHC RNA by antiviral therapy. J Med Virol,2011,83(6):1016-1022. [22] Conjeevaram HS,Kleiner DE,Everhart JE,et al. Race,insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology,2007,45(1):80-87. [23] Grasso A,Malfatti F,Leo PD, et al. Insulin resistance predicts rapid virological response in non-diabetic,non-cirrhotic genotype 1 CHC patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol,2009,51(6):984-990. [24] Miyaaki H,Ichikawa T,Nakao K,et al. Predictive value of suppressor of cytokine signal 3(SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res,2009,39(9):850-855. [25] Mizuta T,Kawaguchi Y,Eguchi Y,et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci, 2010,55(1):183-189. [26] Lavanchy D. The global burden of hepatitis C. Liver Int, 2009,29 (Suppl 1):74-81. [27] Kissebah AH,Peiris AN. Biology of regional body fat distribution:relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev,1989,5(2):83-109. [28] Bahtiyar G,Shin JJ,Sower JR,et al. Association of diabetes and hepatitis C infection:epidemiologic evidence and pathophysiologic insights. Curr Diab Rep,2004,4(3):194-198. [29] Shintani Y,Fujie H,Miyoshi H,et al. Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology,2004,126(3):840-848. |